Debut diabético en paciente con hepatitis C en tratamiento con ledipasvir/sofosbuvir (Harvoni®)

Sergio Vicente-Sánchez; Laura Menéndez Naranjo

doi:10.7399/fh.2017.41.2.10674

Debut diabético en paciente con hepatitis C en tratamiento con ledipasvir/sofosbuvir (Harvoni®)

Sergio Vicente-Sánchez, Laura Menéndez Naranjo

Resumen

Palabras clave

Texto completo:

PDF

Referencias

Link JO, Taylor JG, Xu L, et al. Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J Med Chem 2014;57(6):2033-46.

Gane EJ, Stedman CA, Hyland RH, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 2013;146(3):736-43.

Afdhal N, Reddy KR, Nelson, DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370(16):1483-93.

Jensen CM, Holle LM. Ledipasvir/sofosbuvir: A Once-Daily Oral Treatment Option for Chronic hepatitis C Virus Genotype 1 Infection. Pharmacotherapy, 2016;36(5):562-74.

Premji R, Roopnarinesingh N, MD, Qazi N, Nylen E. New-Onset Diabetes Mellitus exposure to ledipasvir and sofosbuvir. J Investig Med High Impact Case Rep. [revista en internet]. 2015 [citado 29/12/2015];3(4): [aprox 3 pantallas]. Disponible en:http://hic.sagepub.com/content/3/4/2324709615623300.full.pdf+html

Algoritmo de Karch-Lasagna modificado. Centros Autónomos de Farmacovigilancia. Manual de codificación. Madrid: Ministerio de Sanidad y Consumo; 1994.

DOI: http://dx.doi.org/10.7399%2Ffh.2017.41.2.10674